Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
NCT00507429
Terminated
The purpose of the study is to determine the safety and efficacy of combretastatin combined with paclitaxel and carboplatin in the treatment of anaplastic thyroid cancer (ATC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2014
Locations: University of Texas M.D. Anderson Cancer Center, Houston, Texas
Conditions: Anaplastic Thyroid Cancer
Register for Updates
TAXUS PERSEUS Workhorse
NCT00484315
Completed
The purpose of the TAXUS PERSEUS Workhorse trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo atherosclerotic lesions of up to 28 mm in length in native coronary arteries of 2.75 mm to 4.0 mm diameter.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2014
Locations: Baylor Heart & Vascular Hospital, Dallas, Texas +3 locations
Conditions: Coronary Artery Disease
Register for Updates
TAXUS PERSEUS Small Vessel
NCT00489541
Completed
The purpose of the TAXUS PERSEUS Small Vessel trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo atherosclerotic lesions of up to 20 mm in length in native coronary arteries of ≥ 2.25 mm to \< 2.75 mm diameter.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2014
Locations: Methodist DeBakey Heart Center, Houston, Texas +1 locations
Conditions: Coronary Artery Disease
Register for Updates
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
NCT02044601
Withdrawn
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of onartuzumab that can be given with erlotinib and standard chemoradiation (paclitaxel and carboplatin) to patients with NSCLC. The goal of Phase II is to learn if onartuzumab plus erlotinib and chemoradiation can help to control NSCLC. The safety of this drug will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2014
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer
NCT00003253
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some patients may develop a resistance to chemotherapy drugs. PURPOSE: Phase II trial to determine the reliability of a test for measuring drug resistance to paclitaxel in patients with metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2013
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
NCT00596830
Terminated
Determine whether the addition of CP- 751,871 in combination with paclitaxel plus carboplatin prolongs survival in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of non adenocarcinoma histology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2013
Locations: Pfizer Investigational Site, Austin, Texas +17 locations
Conditions: Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
Register for Updates
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
NCT01069328
Completed
To determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2013
Locations: Not set, Houston, Texas
Conditions: Carcinoma, Non-Small-Cell Lung, Lung Cancer
Register for Updates
Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer
NCT00003591
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy plus paclitaxel in treating patients who have nonmetastatic, unresectable pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2013
Locations: Julie and Ben Rogers Cancer Institute, Beaumont, Texas +4 locations
Conditions: Pancreatic Cancer
Register for Updates
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
NCT00147537
Completed
Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when administered with paclitaxel, carboplatin and erlotinib. Phase 2: To test the efficacy of CP-751,871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2013
Locations: Pfizer Investigational Site, Houston, Texas
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer
NCT00002568
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining chemotherapy with surgery may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy consisting of paclitaxel and cisplatin with or without surgery in treating patients with stage III ovarian epithelial cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
07/08/2013
Locations: Simmons Cancer Center - Dallas, Dallas, Texas +1 locations
Conditions: Ovarian Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer
NCT00003378
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients with previously untreated stage III or stage IV ovarian or primary peritoneal cancer.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
07/08/2013
Locations: Simmons Cancer Center - Dallas, Dallas, Texas +1 locations
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT00003691
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy consisting of doxorubicin and cisplatin with or without paclitaxel and G-CSF in treating patients who have stage III, stage IV, or recurrent endometrial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/08/2013
Locations: Simmons Cancer Center - Dallas, Dallas, Texas +2 locations
Conditions: Endometrial Cancer
Register for Updates